Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes

Seon-Ah Cha¹,², Jae-Seung Yun¹, Gee-Hee Kim³ and Yu-Bae Ahn¹*

Abstract

Background: Few studies have examined the association between hypoglycemic episodes among people with type 2 diabetes (T2DM) at the time of hospitalization for heart failure (HF) and cardiovascular outcomes.

Methods: From March 2016 to June 2018, we conducted a retrospective cohort study to investigate hypoglycemia during HF hospitalization in the emergency department, three-point major adverse cardiovascular events (3P-MACE), and all-cause mortality; these were followed up through June 2021. HF hospitalization was defined according to American Heart Association criteria. Hypoglycemia was defined as a glucose level < 3.9 mmol/L at the time of HF hospitalization. We classified the enrolled patients into three groups (reference group, those without T2DM or hypoglycemia; those diagnosed with T2DM without hypoglycemia; and those with hypoglycemia and T2DM). We used Cox proportional hazard regression analysis to investigate the association between the three groups and the development of the first occurrence of 3P-MACE and all-cause mortality.

Results: During a median of 25 months of follow-up, a total of 783 patients admitted due to HF were analyzed. In total, 159 (20.3%) cases of 3P-MACE were identified, and the mortality rate was 20.2% (n = 158). The median age of patients was 76.0 (65.0–82.0) years, and 49.0% were men. Patients with 3P-MACE had a lower body mass index (22.6 [20.4–25.1] vs. 23.8 [21.3–26.7]), higher frequency of previous history of HF (24.5% vs. 15.7%), T2DM (64.2% vs. 47.3%), higher rates of hypoglycemia at the time of HF hospitalization (19.5% vs. 7.7%), and lower eGFR levels (61.1 [36.0–80.7] mL/min/1.73 m² vs. 69.2 [45.8–89.5] mL/min/1.73 m²) than those without 3P-MACE. The multivariable adjusted HR of 3P-MACE was as follows: group with hypoglycemia and T2DM: HR: 2.29; 95% CI: 1.04–5.06; group with T2DM without hypoglycemia: HR: 1.42; 95% CI: 0.86–2.33; and all-cause mortality group with hypoglycemia and T2DM: HR: 2.58; 95% CI: 1.26–5.31, group with T2DM without hypoglycemia: HR: 1.32; 95% CI: 0.81–2.16; compared to the reference group (group without T2DM or hypoglycemia).

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: T2DM and hypoglycemia are independent risk factors for 3P-MACE and all-cause mortality compared to those without hypoglycemia during HF hospitalization.

Keywords: Hypoglycemia, Type 2 diabetes, Heart failure, MACE

Background
In 2019, 9.3% of people aged 20–79 years had type 1 or type 2 diabetes (T2DM) worldwide [1]. In addition, there will be 578 million (10.2%) adults diagnosed with type 1 diabetes or T2DM by 2030. This increase in T2DM has been associated with a higher incidence of micro- and macrovascular complications [1].

Tight glycemic control showed beneficial effects on microvascular complications but inconsistent results on macrovascular complications in patients with T2DM. Strict glycemic control is inevitably associated with an increased risk of hypoglycemia and severe hypoglycemia in T2DM patients [2]. Severe hypoglycemia is associated with unexpected and recurrent morbidity in patients with type 1 diabetes and T2DM and is occasionally fatal [3]. Several studies and post hoc analyses of the Veterans Affairs Diabetes Trial showed that severe hypoglycemia was linked to increased CV disease [4, 5, 5]. Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants also showed that severe hypoglycemia episodes during a 24 month period have a 1.68-fold higher risk of incident HF than those without any episode of hypoglycemia [6]. In addition, a dose–response relationship was observed between severe hypoglycemic episodes and myocardial infarction, stroke, heart failure, and all-cause death in the Korean population with T2DM [7]. Accordingly, current clinical guidelines emphasize that patients with T2DM should be checked for the occurrence and risk of hypoglycemia at every visit [8].

Previous studies reported that 10–47% of patients with HF had T2DM, while T2DM was associated with a three-fold risk of HF compared to those without T2DM [9–11]. Moreover, patients with either type 1 or type 2 diabetes and HF have a 1.7-fold increased risk of myocardial infarction (MI), stroke, or cardiovascular (CV) death at 4 years compared to patients without type 1 diabetes or T2DM [12].

A decreasing trend in major CV complications was observed from 2006 to 2013 in Korea; these complications included hospitalization due to ischemic heart disease (−29.5% vs. −14.7%), MI rate (−37.3% vs. −25.5%), and ischemic stroke rate (−37.0% vs. −28.9%) [13]. However, the prevalence of HF has been increasing in T2DM patients (men, 72–146 per 10,000 adults, women, 124–161 per 10,000 adults) from 2006 to 2015 in Korea [13]. Despite complex medical therapies addressing the underlying causes of HF, including ischemic heart disease, hyperglycemia, dyslipidemia, and hypertension, these patients had substantially higher mortality with T2DM and HF than without T2DM, emphasizing the need to estimate residual risk factors for mortality in T2DM and HF [4, 13].

However, long-term data on the effect of hypoglycemia on adverse CV outcomes in HF hospitalization are limited. Conducting glycemic control research in patients with HF and T2DM is crucial for understanding the target blood glucose level for their treatment. Therefore, the objective of this study was to estimate the CV outcomes and all-cause mortality associated with hypoglycemia and T2DM in patients at the time of HF hospitalization.

Method
Study design and oversight
We performed retrospective cohort study of 783 patients aged ≥ 25 years who were admitted to St. Vincent’s Hospital in South Korea for HF via the emergency department between March 2016 and June 2018, consecutively followed up until June 2021. Patients with gestational diabetes, type 1 diabetes, thyroid disease, and severe illnesses, including liver cirrhosis, malignancy, or sepsis, were excluded from the current investigation. All study protocols were approved by the Institutional Review Board of the Catholic Medical Center Ethics Committee (VC20RISIO253).

Measurements
All participants were interviewed about their medical history and their anthropometric measurements were recorded, as described in prior publications [13]. In brief, information on medical history, medication, and current or past smoking status was obtained [14]. Fasting plasma glucose and lipid profiles were assessed using an automated enzymatic method (736–40; Hitachi, Tokyo, Japan) after 8 h of fasting, and HbA1c was measured using high-performance liquid chromatography (Bio-Rad, Montreal, QC, Canada). The estimated glomerular filtration rate (eGFR) was estimated using the four-component Modification of Diet in Renal Disease equation.

The N-terminal-pro-B-type natriuretic peptide (NT-proBNP) level was measured using an electrochemiluminescence sandwich immunoassay method with an Elecsys 2010 analyzer (Roche Diagnostics, Basel, Switzerland), and high-sensitivity troponin T and creatinine kinase MB isoenzyme were determined using the same method with
Disease (CKD) was defined as at least two measures of eGFR < 60 mL/min/1.73 m² over 3 months or more [17].

### Primary and secondary outcomes

The primary outcome was the first occurrence of three-point major adverse cardiovascular events (3P-MACE), a composite of death from CV causes, nonfatal MI, or nonfatal stroke. Secondary outcomes included all-cause mortality.

If a subject experienced more than one event, the first event was considered in the analysis.

### Statistical analysis

All data are expressed as the mean ± standard deviation for normal distribution, median and interquartile range for non-normal distribution, or frequency. Continuous symmetrical variables were tested using an independent t test, asymmetrical variables were tested using the Mann–Whitney test, and the chi-square test was used for categorical variables.

A Cox proportional hazard regression model was used for the associations between the three groups, 3P-MACE, and all-cause mortality with prespecified covariates of age, sex, body mass index, history of cardiovascular disease (CVD), HF, etiology of HF, presence of CKD, systolic blood pressure (SBP), fasting plasma glucose, HbA1c, use of insulin, sulfonylurea, metformin, antihypertensive medications including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and diuretics including mineralocorticoid receptor antagonists, aspirin, statin, troponin-T, NT-proBNP, CRP, reactive protein, and reduced ejection fraction (EF ≤ 40%). The proportional hazards assumption was estimated using a time interaction term with survival time in the regression model and log–log survival plots. There was no significant departure from proportionality to hazards over time. Potential confounders were identified a priori based on a literature review. Statistical significance was evaluated using two-sided tests, with the level of significance set at 0.05. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).

### Results

#### Study outline

A total of 1309 subjects admitted to St. Vincent’s Hospital due to HF were consecutively screened; 526 subjects were excluded: 431 patients who were misclassified, 32 excluded due to age, 5 with T1DM, and 58 with severe illness, including liver cirrhosis, malignancy, or sepsis. Finally, 783 patients admitted for HF hospitalization from the emergency department were recruited between March 2016 and June 2018 (Fig. 1). A total of 158 (20.2%) patients died, and 159 patients (20.3%) underwent...
3P-MACE during the median follow-up period (interquartile range, 7.0–35.0 months).

**Baseline characteristics**

The median age of the patients was 76.0 (interquartile range, 65.0–82.0) years, and 49.0% were men. The mean left ventricular ejection fraction was 41.9 ± 15.4%. A total of 397 patients (50.7%) had T2DM. The etiology of HF was ischemic heart disease (29.2%) or nonischemic heart disease (70.8%) (Table 2). The median hospital stay was 6.0 days (interquartile range, 4.0–10.0 days).

A total of 386 patients (49.3%) were in the reference group (HF without T2DM or hypoglycemia group), 318 (40.6%) were in the group with T2DM without hypoglycemia, and 79 (10.1%) were in the group with T2DM and hypoglycemia.

Several baseline characteristics were significantly different between the groups. As shown in Table 1, fasting plasma glucose (5.7 ± 0.8 mmol/L, 8.5 ± 4.1, and
| Table 1 Baseline characteristics of patients according to the presence of type 2 diabetes or hypoglycemia with heart failure hospitalization |
|-------------------------------------------------|
| | Heart failure without T2 DM | Heart failure with T2DM without hypoglycemia | Heart failure with T2DM, hypoglycemia | \( P \) value |
| \( n \) | 386 (49.3) | 318 (40.6) | 79 (10.1) |
| Age (years) | 71.6 ± 15.6 | 73.2 ± 11.3 | 72.6 ± 13.7 | 0.269 |
| Male | 196 (50.8) | 147 (46.2) | 41 (51.9) | 0.421 |
| Body mass index (kg/m²) | 22.8 (20.4–26.5) | 24.0 (22.1–26.6) | 23.5 (20.8–26.3) | 0.002 |
| Smoking | | | | 0.095 |
| Current | 66 (17.1) | 48 (15.1) | 8 (10.1) |
| Ex-smoker | 30 (7.8) | 36 (11.3) | 13 (16.4) |
| T2DM | 0 (0.0) | 318 (100.0) | 79 (100.0) | < 0.001 |
| Duration of T2DM (years) | - | 11.2 ± 10.4 | 14.3 ± 11.7 | 0.044 |
| Hypertension | 213 (55.2) | 239 (75.2) | 62 (78.5) | < 0.001 |
| History of CHD | 45 (11.7) | 71 (22.3) | 24 (30.4) | < 0.001 |
| History of stroke | 33 (8.5) | 35 (11.0) | 9 (11.4) | 0.490 |
| Previous HF | 59 (15.3) | 58 (18.2) | 20 (25.3) | 0.092 |
| Duration of HF (years) | 3.2 ± 2.8 | 6.1 ± 5.3 | 3.8 ± 3.1 | 0.026 |
| Etiology of HF | | | | < 0.001 |
| Ischemic cause (coronary artery disease or myocardial infarction) | 85 (22.0) | 110 (34.6) | 34 (43.0) |
| Nonischemic cause | 301 (78.0) | 208 (65.4) | 45 (57.0) |
| Chronic kidney disease | 107 (27.7) | 166 (52.2) | 54 (68.4) | < 0.001 |
| Systolic blood pressure (mm Hg) | 129.0 ± 26.2 | 135.0 ± 28.8 | 135.1 ± 26.4 | 0.010 |
| Diastolic blood pressure (mm Hg) | 77.9 ± 15.8 | 80.3 ± 16.7 | 77.8 ± 13.6 | 0.126 |
| Heart rate (beats per min) | 92.5 ± 23.7 | 92.8 ± 21.9 | 93.7 ± 23.3 | 0.910 |
| Left ventricular ejection fraction (%) | 41.3 ± 15.9 | 43.5 ± 15.0 | 38.7 ± 14.6 | 0.029 |
| E/e’ | 19.0 ± 9.5 | 21.0 ± 10.2 | 20.9 ± 9.0 | 0.020 |
| Laboratory variables | | | | |
| FPG (mmol/L) | 5.7 ± 0.8 | 8.5 ± 4.1 | 3.3 ± 0.7 | < 0.001 |
| HbA1c (%) | 5.7 ± 0.5 | 7.3 ± 3.3 | 7.8 ± 1.8 | < 0.001 |
| eGFR (mL min⁻¹ 1.73 m⁻²) | 74.8 (56.7–99.6) | 57.1 (36.5–83.8) | 45.9 (29.4–69.2) | < 0.001 |
| Total cholesterol (mmol/L) | 3.9 ± 1.0 | 3.8 ± 1.1 | 3.5 ± 1.8 | 0.072 |
| Triglyceride (mmol/L) | 0.3 (0.7–1.1) | 1.0 (0.8–1.4) | 0.8 (0.7–1.1) | < 0.001 |
| HDL-C (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.4 | 1.1 ± 0.3 | 0.140 |
| LDL-C (mmol/L) | 2.4 ± 0.8 | 2.4 ± 0.9 | 2.2 ± 0.9 | 0.105 |
| NT-pro BNP (pg/mL) | 3900 (1707–7928) | 4250 (1828–9598) | 7485 (3266–24,153) | < 0.001 |
| hsTnT (ng/L) | 25.0 (16.0–50.5) | 32.0 (18.0–75.5) | 66.0 (27.0–133.3) | < 0.001 |
| CK-MB (ng/ml) | 3.2 (2.1–5.6) | 3.1 (2.1–5.5) | 4.1 (2.4–6.3) | 0.104 |
| CPK (U/L) | 104.0 (69.0–174.5) | 103.0 (66.0–166.5) | 104.0 (62.0–164.0) | 0.722 |
| CRP (mg/dl) | 0.5 (0.2–1.7) | 0.5 (0.2–2.1) | 1.0 (0.2–3.2) | 0.132 |
| Medication | | | | |
| Cardiovascular medication | | | | |
| ACEi/ARB | 115 (29.8) | 122 (38.4) | 29 (36.7) | 0.050 |
| ß-blocker | 84 (21.8) | 98 (30.9) | 25 (31.6) | 0.013 |
| CCB | 60 (15.5) | 96 (30.4) | 28 (35.4) | < 0.001 |
| Diuretics | 148 (38.3) | 143 (45.0) | 45 (57.0) | 0.006 |
| Aspirin | 77 (19.9) | 87 (27.4) | 26 (32.9) | 0.012 |
| Statin | 68 (17.6) | 106 (33.3) | 29 (36.7) | < 0.001 |
| Diabetes treatment | | | | |
| Insulin | 0 (0.0) | 29 (9.1) | 11 (13.9) | 0.204 |
| Sulfonylurea | 0 (0.0) | 59 (18.6) | 30 (38.0) | < 0.001 |
Table 1 (continued)

|                           | Heart failure without T2 DM | Heart failure with T2DM without hypoglycemia | Heart failure with T2DM, hypoglycemia | P value |
|---------------------------|----------------------------|---------------------------------------------|--------------------------------------|---------|
| Metformin                 | 0 (0.0)                    | 94 (29.6)                                   | 26 (32.9)                           | 0.562   |
| DPP-4 inhibitor           | 0 (0.0)                    | 99 (31.1)                                   | 28 (35.4)                           | 0.462   |

Data are number (percentage) or medians with 25th–75th percentiles, means ± SD. *P < 0.05 was considered significant

CHD coronary heart disease, T2DM type 2 diabetes, FPG fasting plasma glucose, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP N-terminal pro-B type natriuretic peptide, hTnT High-sensitivity troponin T, CRP C-reactive protein, ACEi/ARB ACE inhibitor/angiotensin receptor blocker, CCB calcium channel blocker

3.3±0.7 mmol/L, *p < 0.001), Hba1c level (5.7±0.5%, 7.3±3.3%, and 7.8±1.8%, *p < 0.001), eGFR (74.8 [56.7–99.6] mL/min/1.73 m², 57.1 [36.5–83.8] mL/min/1.73 m², and 45.9 [29.4–69.2] mL/min/1.73 m², *p < 0.001) showed significant differences among the three groups. The group with T2DM and hypoglycemia had a reduced left ventricular ejection fraction (38.7±14.6% vs. 43.5±15.0%, *p = 0.029) compared with those with T2DM without hypoglycemia (Table 1).

During a median follow-up period of 25 months, 159 patients (20.3%) developed 3P-MACE. Compared to those without 3P-MACE, patients with 3P-MACE had a lower body mass index (22.6 [20.4–25.1] kg/m² vs. 23.8 [21.3–26.7] kg/m², *p = 0.002), a higher frequency of history of T2DM (64.2% vs. 47.3%, *p < 0.001), hypoglycemia at HF hospitalization (19.5% vs. 7.7%, *p < 0.001), previous diagnosis of HF (24.5% vs. 15.7%, *p = 0.009), CKD (49.7% vs. 39.7%, *p = 0.023), and higher high-sensitivity troponin T levels (54.0 [27.0–122.8] ng/L vs. 26.0 [16.0–55.5] ng/L, *p < 0.001), NT-pro-BNP levels (7490 [3002–19361] pg/mL vs. 3825 [1603–7922] pg/mL, *p < 0.001) than patients without 3P-MACE (Table 2).

In addition, there was a higher use of sulfonylurea (16.4% vs. 10.1%) in patients with 3P-MACE than in those without 3P-MACE.

The median time from HF hospitalization to 3P-MACE was 7 months (interquartile range 1.0–19.0 months). Of the 159 patients who developed 3P-MACE, 31 (19.2%) were in the group with T2DM and hypoglycemia, 71 (22.3%) were in the group with T2DM without hypoglycemia, and 57 (14.8%) were in the reference group (those without T2DM or hypoglycemia) (*p for trend < 0.001).

Relationship between type 2 diabetes, hypoglycemia, 3P-MACE, and all-cause mortality

Table 3 and Additional file 1: Table S3 show that the presence of T2DM and hypoglycemia (blood glucose ≤ 3.9 mmol/L) at the time of HF hospitalization was a significant risk factor for 3P-MACE.

In addition, the impact of hypoglycemia on 3P-MACE was substantially greater (HR: 2.29; 95% CI: 1.04–5.06) than that of the reference group (those without T2DM or hypoglycemia) after adjusting for age, sex, body mass index, diabetes duration (> 10 years), history of CVD, HF, etiology of HF, presence of CKD, SBP, fasting plasma glucose, Hba1c, use of insulin, sulfonylurea, anti-hypertensive medication, statin, levels of high-sensitivity troponin T, NT-proBNP, and C-reactive protein. In terms of the T2DM without hypoglycemia group, the HR was greater than that of the reference group (those without T2DM or hypoglycemia), but the difference was not significant.

Moreover, body mass index (*p = 0.006), history of HF (*p = 0.008), SBP (*p = 0.001), and NT-proBNP level (*p = 0.010) were also independent covariates for 3P-MACE in HF patients in this study (Additional file 1: Table S3).

There were no significant interactions between the effect of hypoglycemia and body mass index (*p-interaction = 0.866), SBP (*p-interaction = 0.243), use of sulfonylurea (*p-interaction = 0.101), use of insulin (*p-interaction = 0.934), and NT-proBNP (*p-interaction = 0.810) on the risk of 3P-MACE. A significant interaction of the effect of hypoglycemia and previous HF with the risk of 3P MACE was observed in this study (*p for interaction = 0.036).

The cumulative hazard rate (HR) of the development of incident 3P MACE and all-cause mortality according to T2DM or hypoglycemia is shown in Fig. 2. The highest rate of all-cause mortality was noted in the group with T2DM and hypoglycemia. Thirty-three patients (42.3%) in the group with T2DM and hypoglycemia, 70 patients (21.9%) in the group with T2DM without hypoglycemia, and 55 patients (14.2%) in the reference group (those without T2DM or hypoglycemia) died, and the HR of the group with T2DM and hypoglycemia for all-cause mortality was 2.58 (95% CI: 1.26–5.31) (*p for trend = 0.002).

The mortality rate at 1 year was 12.7% in all patients with HF, 10.1% in the reference group, 11.0% in the group with T2DM without hypoglycemia, and 32.9% in the group with T2DM and hypoglycemia. The mortality rate at 2 years was 17.6% (138) in patients with HF, 13.5% in the reference group (those without T2DM or hypoglycemia), 17.0% in the group with T2DM without
Table 2  Baseline characteristics according to the development of incident three-point major adverse cardiovascular events (3P-MACE) in patients with heart failure hospitalization

|                              | Total (n = 783) | 3P MACE (-) (n = 624) | 3P MACE (+) (n = 159) | P value |
|------------------------------|----------------|------------------------|-----------------------|---------|
| Age (years)                  | 72.3 ± 13.8    | 72.4 ± 13.9            | 71.7 ± 13.8           | 0.472   |
| Male                         | 384 (49.0)     | 297 (47.6)             | 87 (54.7)             | 0.109   |
| Body mass index (kg/m²)      | 23.5 (21.2–26.5) | 23.8 (21.3–26.7)      | 22.6 (20.4–25.1)      | 0.002   |
| Smoking (current)            | 122 (15.6)     | 95 (15.2)              | 27 (17.0)             | 0.390   |
| T2DM                         | 397 (50.7)     | 295 (47.3)             | 102 (64.2)            | < 0.001 |
| Duration of T2DM (years)     | 12.0 ± 10.8    | 12.2 ± 10.9            | 11.2 ± 10.7           | 0.484   |
| Hypertension                 | 514 (65.6)     | 402 (64.4)             | 112 (70.4)            | 0.154   |
| History of CHD               | 140 (17.9)     | 101 (16.2)             | 39 (24.5)             | 0.014   |
| History of stroke            | 77 (9.8)       | 60 (9.6)               | 17 (10.7)             | 0.684   |
| History of heart failure     | 137 (17.5)     | 98 (15.7)              | 39 (24.5)             | 0.009   |
| Duration of HF (years)       | 4.6 ± 4.4      | 5.3 ± 5.0              | 3.6 ± 2.9             | 0.206   |
| Etiology of heart failure    |               |                        |                      | 0.002   |
| Ischemic cause (coronary artery disease or myocardial infarction) | 229 (29.2) | 167 (26.8) | 62 (39.0) |
| Nonischemic cause            | 554 (70.8)     | 457 (73.2)             | 97 (61.0)             |         |
| Chronic kidney disease       | 317 (41.8)     | 248 (39.7)             | 79 (49.7)             | 0.023   |
| Systolic blood pressure (mm Hg) | 132.0 ± 27.4 | 133.1 ± 27.4          | 128.1 ± 27.5          | 0.101   |
| Diastolic blood pressure (mm Hg) | 79.0 ± 16.0   | 79.5 ± 15.9            | 76.4 ± 16.2           | 0.056   |
| Heart rate (beats per min)   | 92.7 ± 23.0    | 92.6 ± 23.3            | 93.1 ± 21.8           | 0.397   |
| Left ventricular ejection fraction (%) | 41.9 ± 15.4 | 43.2 ± 15.5          | 36.8 ± 14.1           | < 0.001 |
| E/e'                         | 19.9 ± 9.7     | 19.3 ± 9.2             | 23.0 ± 11.2           | < 0.001 |
| Hypoglycemia during hospitalization | 79 (10.1) | 48 (7.7)              | 31 (19.5)             | < 0.001 |
| Laboratory variables         |               |                        |                      |         |
| FPG (mmol/L)                 | 6.6 ± 3.2      | 6.6 ± 3.0              | 6.9 ± 4.0             | 0.754   |
| HbA1c (%)                    | 6.7 ± 2.5      | 6.7 ± 2.7              | 7.0 ± 1.6             | 0.002   |
| eGFR (mL min⁻¹ 1.73 m⁻²)     | 66.8 (45.0–87.7) | 69.2 (45.8–89.5)      | 61.1 (36.0–80.7)      | 0.003   |
| Total cholesterol (mmol/L)   | 3.8 ± 1.1      | 3.8 ± 1.0              | 3.8 ± 1.1             | 0.916   |
| Triglyceride (mmol/L)        | 0.9 (0.7–1.2)  | 0.9 (0.7–1.2)          | 0.9 (0.7–1.1)         | 0.962   |
| HDL-C (mmol/L)               | 1.1 ± 0.3      | 1.1 ± 0.3              | 1.1 ± 0.3             | 0.456   |
| LDL-C (mmol/L)               | 2.4 ± 0.9      | 2.4 ± 0.8              | 2.5 ± 0.9             | 0.533   |
| NT-pro BNP (pg/mL)           | 4238 (1860–9302) | 3825 (1603–7922)     | 7490 (3002–19,361)    | < 0.001 |
| hsTnT (ng/L)                 | 29.0 (17.0–65.0) | 26.0 (16.0–55.5)      | 54.0 (27.0–122.8)     | < 0.001 |
| CK-MB (ng/ml)                | 3.2 (2.1–5.6)  | 3.2 (2.1–5.4)          | 3.7 (2.2–6.8)         | 0.044   |
| CPK (U/L)                    | 104.0 (68.5–170.0) | 103.0 (69.0–167.3)   | 105.0 (65.0–191.0)    | 0.891   |
| CRP (mg/dl)                  | 0.5 (0.2–2.0)  | 0.5 (0.2–1.8)          | 0.8 (0.3–2.9)         | 0.010   |
| Medication                   |               |                        |                      |         |
| ACEi/ARB                     | 266 (34.0)     | 214 (34.3)             | 52 (32.7)             | 0.705   |
| ß-blocker                    | 207 (26.5)     | 170 (27.3)             | 37 (23.3)             | 0.305   |
| CCB                          | 184 (23.6)     | 149 (24.0)             | 35 (22.0)             | 0.607   |
| Diuretics                    | 336 (42.9)     | 252 (40.4)             | 84 (52.8)             | 0.005   |
| Aspirin                      | 190 (24.3)     | 148 (23.7)             | 42 (26.4)             | 0.479   |
| Statin                       | 203 (25.9)     | 162 (26.0)             | 41 (25.8)             | 0.964   |
| Diabetes treatment           |               |                        |                      |         |
| Insulin                      | 40 (5.1)       | 32 (5.1)               | 8 (5.0)               | 0.961   |
Table 2 (continued)

| Total (n = 783) | 3P MACE (-) (n = 624) | 3P MACE (+) (n = 159) | P value |
|----------------|------------------------|-----------------------|---------|
| Sulfonylurea   | 89 (11.4)              | 63 (10.1)             | 26 (16.4) | 0.027 |
| Metformin      | 120 (15.3)             | 88 (14.1)             | 32 (20.1) | 0.060 |
| DPP-4 inhibitor| 127 (16.2)             | 94 (15.1)             | 33 (20.8) | 0.082 |

Data are number (percentage) or medians with 25th–75th percentiles, means ± SD. P < 0.05 was considered significant.

CHD coronary heart disease, T2DM type 2 diabetes, FPG fasting plasma glucose, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP N-terminal-pro-B-type natriuretic peptide, hsTnT High-sensitivity troponin T, CRP C-reactive protein, ACEi/ARB ACE inhibitor/angiotensin receptor blocker, CCB calcium channel blocker

Table 3 Increased risk for cardiovascular events and all-cause mortality according to presence of type 2 diabetes or hypoglycemia in heart failure hospitalization

| Patients without T2DM | Patients with T2DM without hypoglycemia | Patients with T2DM and hypoglycemia |
|-----------------------|----------------------------------------|-----------------------------------|
| HR (95% CI)           | HR (95% CI)                            | HR (95% CI)                        |
| 3P-MACE               |                                        |                                   |
| No. of cases (%)      | 57 (14.8)                              | 71 (22.3)                         | 31 (39.2) |
| Model 1<sup>a</sup>   | 1 [Reference]                          | 1.39 (0.98–1.97)                  | 2.67 (1.72–4.15) |
| Model 2<sup>b</sup>   | 1 [Reference]                          | 1.64 (1.06–2.55)                  | 3.53 (1.92–6.49) |
| Model 3<sup>c</sup>   | 1 [Reference]                          | 1.42 (0.86–2.33)                  | 2.29 (1.04–5.06) |
| Cardiovascular mortality |                                    |                                   |
| No. of cases (%)      | 37 (9.6)                               | 37 (11.6)                         | 22 (27.8) |
| Model 1<sup>a</sup>   | 1 [Reference]                          | 1.14 (0.72–1.81)                  | 3.28 (1.93–5.56) |
| Model 2<sup>b</sup>   | 1 [Reference]                          | 1.46 (0.83–2.56)                  | 4.95 (2.35–10.42) |
| Model 3<sup>c</sup>   | 1 [Reference]                          | 1.12 (0.61–2.07)                  | 2.87 (1.17–7.05) |
| All-cause mortality   |                                        |                                   |
| No. of cases (%)      | 55 (14.2)                              | 69 (21.7)                         | 34 (43.0) |
| Model 1<sup>a</sup>   | 1 [Reference]                          | 1.42 (1.00–2.02)                  | 3.37 (2.15–5.19) |
| Model 2<sup>b</sup>   | 1 [Reference]                          | 1.74 (1.13–2.69)                  | 4.53 (2.52–8.16) |
| Model 3<sup>c</sup>   | 1 [Reference]                          | 1.32 (0.81–2.16)                  | 2.58 (1.26–5.31) |

HR, hazard ratio, CI confidence interval, T2DM, type 2 diabetes
<sup>a</sup> Model 1 was adjusted for age and sex
<sup>b</sup> Model 2 additionally included body mass index, current smoking status, presence of previous coronary heart disease, stroke, heart failure, etiology of heart failure, duration of diabetes (if subjects had T2DM), systolic blood pressure, fasting plasma glucose, HbA1c ≥ 7%, and presence of chronic kidney disease (eGFR ≤ 60 mL/min/1.73 m<sup>2</sup>)
<sup>c</sup> Model 3 additionally included use of antihypertensive medications, statins, insulin, sulfonylurea, high-sensitivity troponin T, N-terminal-pro-B-type natriuretic peptide, C-reactive protein level, and reduced EF (EF ≤ 40%)

hypoglycemia, and 40.5% in the group with T2DM and hypoglycemia.

Older age (p = 0.022), lower body mass index (p < 0.001), history of HF (p = 0.023), SBP (p = 0.012), high-sensitivity troponin T (p = 0.025), and NT-proBNP (p = 0.002) were also significant predictors of all-cause mortality. However, there were no significant interactions between the effects of hypoglycemia and age (p-interaction = 0.810), body mass index (p-interaction = 0.387), SBP (p-interaction = 0.703), high-sensitivity troponin T (p-interaction = 0.423), and NT-proBNP (p-interaction = 0.685) on the risk of all-cause mortality.

A similar result was found for CV mortality (Table 3): T2DM and hypoglycemia were a significant predictors of CV mortality (HR: 2.87; 95% CI: 1.17–7.05, group with T2DM without hypoglycemia; HR: 1.12; 95% CI: 0.61–2.07) compared to the reference group (those without T2DM or hypoglycemia).
Discussion
This study found that hypoglycemia and T2DM were associated with increased overall mortality and adverse CV outcomes compared to patients without T2DM during HF hospitalization from the emergency department, even after adjusting for multiple covariates. Covariates for CV outcome and all-cause mortality included age, sex, body mass index, diabetes duration, smoking status, history of CVD, history and etiology of HF, SBP, fasting plasma glucose, HbA1c, CKD (eGFR $\leq$ 60 mL/min/1.73 m$^2$), presence of systolic HF (EF $\leq$ 40%), use of antihypertensive drugs, insulin, sulfonylurea, statins, high-sensitivity troponin T, NT-proBNP, and C-reactive protein levels. Among the components of 3P-MACE, the presence of T2DM and hypoglycemia has a greater association with the development of CV mortality and nonfatal MI. To our knowledge, this study is one of the first to investigate the effect of hypoglycemia in HF hospitalization on 3P-MACE and all-cause mortality.

Type 2 DM in heart failure
Previous studies have shown that chronic hyperglycemia is associated with the risk of HF in T2DM, with a 1.15-fold risk for HF proportional to an increase of 1% in HbA1c [18]. HF is related to increased mortality and CV mortality; in particular, the clinical outcome appears worse in T2DM and even in prediabetes [19]. T2DM is related to significant changes in myocardial structure and function via overt myocardial ischemia and an increased risk of HF, the so-called cardiovascular disease continuum [20–22]. T2DM is also associated with higher levels of atherogenic dyslipidemia, which leads to thrombosis, inflammation, plaque ulceration, accumulation of advanced glycation end-products that cross-link extracellular matrix proteins and transduce fibrogenic signals, endothelial dysfunction, and oxidative stress [9, 23].

Hypoglycemia in heart disease, heart failure
The combination of hypoglycemia and T2DM had a stronger negative impact on 3P-MACE and all-cause mortality among HF hospitalizations than T2DM without hypoglycemia in this study. Aguilar et al. showed that the association between baseline HbA1c in T2DM and HF and all-cause mortality appears U-shaped, with the lowest risk of all-cause mortality at HbA1c of 7.1–7.8% [24]. A similar result was shown in a general HF population in a UK study [25]. In addition, an observational cohort study showed a U-shaped relationship between time-weighted mean HbA1c and mortality, which showed the lowest risk in patients with HbA1c of 7.1–8.0%, and the U-shape is present in drug-treated but not in diet-treated T2DM [26]. This result corresponds to the Action to Control Cardiovascular Risk in Diabetes trials.

Fig. 2 Cumulative hazard rate of the development of cardiovascular outcome and all-cause mortality according to the presence of T2DM and hypoglycemia in patients with heart failure hospitalized in the emergency department. HR, hazard ratio, T2DM; type 2 diabetes
which revealed increased mortality in the intensive treatment group, indicating the potential role of treatment-associated hypoglycemia on adverse cardiovascular outcomes in the T2DM population [27]. Severe hypoglycemia is also known to increase CV risk in the Atherosclerosis Risk in Communities study, which showed a twofold risk of incident or recurrent CVD and a 1.7-fold risk of all-cause mortality [5].

We hypothesized that hypoglycemic events in patients with T2DM might have clinical and prognostic implications in patients hospitalized for HF from the emergency department. Thus, we compared the adverse cardiovascular outcomes and all-cause mortality according to the presence of T2DM and hypoglycemia (reference group: HF without T2DM or hypoglycemia, HF with T2DM without hypoglycemia, HF with T2DM and hypoglycemia) at the time of HF hospitalization and follow-up. In this study, subjects in the group with T2DM and hypoglycemia had higher HbA1c levels than those in the group with T2DM without hypoglycemia (7.8 ± 1.8% vs. 7.3 ± 3.3%, p = 0.004), suggesting that the group with T2DM and hypoglycemia patients might have a higher risk of hypoglycemia with intensified T2DM treatment, which corresponds to ACCORD and the Outcome Reduction With Initial Glargine Intervention trial, which showed severe hypoglycemia in the standard therapy group who experienced a higher relative risk of all-cause mortality [28, 29].

Subjects included in the group with T2DM and hypoglycemia might be in a high-risk state because of the reduced ejection fraction and increased NT-proBNP and high-sensitivity troponin T levels, followed by a high rate of 3P-MACE and increased mortality in HF hospitalization. However, significant associations of hypoglycemic events in HF hospitalization persisted after adjustment for multiple covariates, including SBP, glycemic status, reduced EF, biomarkers, and traditional CV risk factors. Thus, clinicians should pay more attention to avoiding hypoglycemia during HF hospitalization to reduce the risk of increased mortality and adverse CV outcomes.

In this study, a lower body mass index was also associated with an increase in 3P-MACE and all-cause mortality, indicating poor prognosis in HF, which may be associated with poor nutrition or a general unhealthy state that results in weight loss [30].

As in this study, prior studies reported that lower SBP < 100 mm Hg continued to be associated with higher mortality and CV mortality in systolic HF patients [31, 32]. Hypertension often precedes the development of HF and causes mortality in HF. The lower BP in patients with HF may be due to antihypertensive drugs or a state of more advanced HF and low cardiac output [32].

### Potential mechanism of hypoglycemia and T2DM in HF patients

The association between hypoglycemia and T2DM in HF hospitalization may be supported by a potential mechanism. Hypoglycemia is linked to coronary artery calcification in T2DM after modifying glycemic control status, which might be associated with profound surges in the sympathoadrenal system as a counterregulatory mechanism, leading to increased cardiac workload and transient ischemia or cardiac failure. Hypoglycemia is also associated with an increase in proinflammatory markers and cytokines related to endothelial dysfunction, which contributes to atherosclerosis [33, 34].

Hypoglycemia can induce increased myocardial electrical vulnerability and vascular thrombosis [34]. Suggested mechanisms include cardiac arrhythmia, prolongation of cardiac repolarization, and hypoglycemia-associated autonomic failure, which may be associated with lethal ventricular arrhythmia. The association between baseline QTc and CV mortality has been reported in patients with T2DM [35]. Insulin-induced hypoglycemia causes catecholamine, including epinephrine, release and increases the QTc interval [36].

In addition, increased high-sensitivity troponins and natriuretic peptides, including NT-proBNP, are well-known, substantial prognostic biomarkers for acute HF, reflecting subclinical myocardial structural changes, thus providing useful information about underlying disease progression [37]. The group with T2DM and hypoglycemia subjects were in acute HF and showed increased high-sensitivity troponin T and NT-proBNP levels compared with the reference group (those without T2DM or hypoglycemia) or the group with T2DM without hypoglycemia, thus indicating poorer prognoses for cardiovascular outcomes and all-cause mortality. Thus, hypoglycemia and T2DM are associated with all, or a combination, of these mechanisms and could be related to increased mortality and adverse CV outcomes at HF hospitalization.

### Limitations

This study has several limitations. First, this was a retrospective, observational design with a small number of participants. The number of those with T2DM and hypoglycemia was small, and the baseline characteristics of participants were discordant according to the presence of hypoglycemia and T2DM. This study might have had the remaining unmeasured confounding variables leading to biased results. Thus, we could not control for all confounding factors influencing CV outcomes and mortality, although we tried to minimize this effect by adjusting for multiple conventional risk factors. In addition, fasting...
plasma glucose, HbA1c, renal function, and cardiac biomarkers were confirmed only once, and we could not evaluate the serial changes after HF hospitalization or the effect of changes in variables on incident MACE effects. Further prospective studies are needed to confirm the causal relationship between hypoglycemia and adverse CV outcomes in patients with HF.

Second, we only have data on the Korean population.

Conclusion
This study suggests that hypoglycemia in T2DM is an independent risk factor for 3P-MACE and all-cause mortality compared to those without hypoglycemia in HF hospitalization from the emergency department. The relationship between hypoglycemia in T2DM and cardiovascular outcome was independent of traditional CV risk factors and the value of several biomarkers, including high-sensitivity troponin T, NT-proBNP, and C-reactive protein. Clinicians should pay more attention to preventing and reducing the risk of hypoglycemia in hospitalized patients with HF. Further studies are needed to investigate the pathogenic mechanism of hypoglycemia for adverse CV outcomes and increased mortality in HF patients.

Abbreviations
T2DM: Type 2 diabetes; HF: Heart failure; MI: Myocardial infarction; CV: Cardiovascular; eGFR: Estimated glomerular filtration rate; NT-pro BNP: N-terminal-pro-B-type natriuretic peptide; CKD: Chronic kidney disease; 3P-MACE: Three-point major adverse cardiovascular events; CVD: Cardiovascular disease; SBP: Systolic blood pressure.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01651-0.

Additional file 1: Table S1. Baseline characteristics according to the presence of hypoglycemia in patients with T2DM and heart failure. Table S2. Adverse cardiovascular outcome and all-cause mortality according to group. Table S3. Multivariable Cox hazard regression model for the adverse cardiovascular outcome and all-cause mortality in patients with heart failure.

Acknowledgements
Not applicable.

Author contributions
SAC analyzed data and wrote the manuscript. JSY acquired and researched data and reviewed and edited the manuscript. GHK reviewed and edited the manuscript. YBA designed the study and the guarantor of this work. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The data of this study may be available on reasonable request to the corresponding author.

Declarations

Ethics approval and consent to participate
This study protocol was approved by the Institutional Review Board of the Catholic Medical Center Ethics Committee in accordance with the ethical principles described in the latest version of the Declaration of Helsinki.

Consent for publication
All the authors listed have approved the manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Endocrinology & Metabolism, Department of Internal Medicine, College of Medicine, St. Vincent’s Hospital, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Seoul, Republic of Korea. 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo, Republic of Korea. 3 Division of Cardiology, Department of Internal Medicine, College of Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

Received: 18 April 2022 Accepted: 23 September 2022
Published online: 21 October 2022

References
1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
2. Davis SN, Duckworth W, Emanuele N, Hayward RA, Wiitala WL, Thot- tapurathu L, et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care. 2019;42(1):157–63.
3. Cryer PE, Davis SN, Shamoona H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–12.
4. Oktay AA, Aktürk HK, Paul TK, O’Keefe JH, Ventura HO, Koch CA, et al. Diabetes, Cardiomyopathy, and Heart Failure. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2020, MDText.com, Inc.; 2000.
5. Echouffo-Tcheugui JB, Daya N, Lee AK, Tang O, Ndumele CE, Windham BG, et al. Severe hypoglycemia, cardiac structure and function, and risk of cardiovascular events among older adults with diabetes. Diabetes Care. 2021;44(1):248–54.
6. Desouza CV, Bollini GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33(6):1389–94.
7. Echouffo-Tcheugui JB, Kaze AD, Fonarow GC, Dagogo-Jack S. Severe hypoglycemia and incident heart failure among adults with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(3):e955–62.
8. Yun JS, Park YM, Han K, Cha SA, Ahn YB, Ko SH. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2019;18(1):103.
9. Targets G. Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73–s84.
10. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–324.
11. Einaron TR, Acs A, Ludwig C, Pantoni UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.
12. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614–9.

13. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherosclerosis for Continued Health (REACH) Registry. Circulation. 2013;128(10):923–31.

14. Park JH, Ha KH, Kim BY, Lee JH, Kim DJ. Trends in cardiovascular complications and mortality among patients with diabetes in South Korea. Diabetes Metab J. 2021;45(1):120–4.

15. Cha SA, Park YM, Yun JS, Lee SH, Ahn YB, Kim SR, et al. Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;135:159–69.

16. Douglas PS, Carabello BA, Lang RM, Lopez L, Pellikka PA, Picard MH, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.

17. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137(9):961–72.

18. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.

19. Ikram MA, Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850–70.

20. Thomas MC. Type 2 Diabetes and Heart Failure: Challenges and Solutions. Curr Cardiol Rev. 2016;12(3):249–55.

21. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzer J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114(25):2850–70.

22. Thomas MC. Type 2 Diabetes and Heart Failure: Challenges and Solutions. Curr Cardiol Rev. 2016;12(3):249–55.

23. Rhee EJ, Kwon H, Park SE, Han KD, Park YG, Kim YH, et al. Associations among Obesity Degree, Glycemic Status, and Risk of Heart Failure in 9,720,220 Korean Adults. Diabetes Metab J. 2020;44(4):592–601.

24. Paolillo S, Marsico F, Prastaro M, Renga F, Esposito L, De Martino F, et al. Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications. Heart Fail Clin. 2019;15(3):341–7.

25. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of heart rate variability with cardiac autonomic failure in diabetes mellitus: a systematic review and meta-analysis. Eur J Heart Fail. 2013;15(2):185–93.

26. Circulation: Heart Failure. Circulation Heart failure. 2016;9(1):e000010.

27. Elder DH, Singh JS, Levin D, Donnelly LA, Choy AM, George J, et al. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2016;18(1):94–102.

28. Gaede P, Lund-Andersen H, Parving HH, Pederson O. Effect of a multifac torial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91.

29. Bonds DE, Miller ME, Bergenthal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ (Clinical research ed). 2010;340: b4909.

30. Melbin LG, Rydén L, Riddle MC, Probstfield J, Rosenstock J, Díaz R, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34(4):3137–44.

31. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75.